Skip to main content

bioAffinity Technologies, Inc.

BIAFW
Exchange
Nasdaq
Industry
Services-Commercial Physical & Biological Research
SEC CIK
0001712762

No open-market purchases or sales by bioAffinity Technologies, Inc. insiders were filed in the last 90 days; 4 institutions reported holding it in 13F filings for Q2 2026, worth $18.1K in total; no superinvestor holds it.

Other share classesBIAF

Key figures

Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, 0 vs. previous quarter
4
13F valueReported value at the end of Q2 2026
$18.1K
Superinvestors holdingAt the end of Q2 2026
0

Price chart

Superinvestors holding BIAFW, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding BIAFW at the end of Q2 2026.

Latest insider trades

Open-market purchases and sales by bioAffinity Technologies, Inc. insiders from Form 4, newest first.

See all insider trades
Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 5, 2022 (view filing)Aug 3196 daysLateKnight Peter SDirectorPPurchaseCommon Stock, par value $0.007+8.16K––+57.1%22.4K after
Dec 5, 2022 (view filing)Aug 3196 daysLateKnight Peter SDirectorPPurchase+16.3K–––8.16K afterDerivative2 lots
Dec 2, 2022 (view filing)Aug 3193 daysLateAnderson Robert A.DirectorPPurchaseCommon Stock, par value $0.007+4.08K––New position4.08K after
Dec 2, 2022 (view filing)Aug 3193 daysLateAnderson Robert A.DirectorPPurchase+8.16K–––4.08K afterDerivative2 lots
Dec 2, 2022 (view filing)Aug 3193 daysLateDiamond StuartDirectorPPurchaseCommon Stock, par value $0.007+4.08K––New position4.08K after
Dec 2, 2022 (view filing)Aug 3193 daysLateDiamond StuartDirectorPPurchase+8.16K–––4.08K afterDerivative2 lots
Nov 29, 2022 (view filing)4:19 PM ETSep 189 daysLateEdwards James MichaelChief Financial OfficerPPurchaseCommon Stock, par value $0.007+2.45K––+8.8%30.3K after
Nov 29, 2022 (view filing)4:19 PM ETSep 189 daysLateEdwards James MichaelChief Financial OfficerPPurchase+4.90K–––2.45K afterDerivative2 lots
Nov 22, 2022 (view filing)1:54 PM ETAug 3183 daysLateZannes MariaPresident, CEOPPurchase+16.3K––+457.2%19.9K after
Nov 22, 2022 (view filing)1:54 PM ETAug 3183 daysLateZannes MariaPresident, CEOPPurchase+32.7K–––16.3K afterDerivative2 lots

Top 10 13F holders, Q2 2026

The largest institutional positions in bioAffinity Technologies, Inc. at the end of Q2 2026; share changes are against Q1 2026.

See all 4 holders
Institutions holding BIAFW in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Clear Street Group Inc.54,927$7.66K0.00%00.0%Unchanged
UBS Group AG46,445$6.50K0.00%+336+0.7%Added
Citadel Advisors LLC17,162$2.39K0.00%−2,688−13.5%Reduced
Susquehanna International Group, LLP11,180$1.55K0.00%+167+1.5%Added